Jeffrey H Lipton, PhD, MD, FRCPC

I am involved in clinical research at the phase I, II and III levels on the therapy of chronic myeloid leukemia. This involves targeted therapy with kinase inhibitors, drugs that may target the CML stem cell and cells that are resistant to other therapies. The interest in targeted therapy extends into the phase II study of signal transduction inhibitors in the therapy of other diseases such as systemic mastocytosis and mast cell leukemia.

The second aspect of my clinical research involves outcome analysis in allogeneic stem cell transplant and the prevention and therapy of side effects. I am particularly interested in donor selection, graft types and therapy of chronic side effects. I am also interested in long term effects on patients who are out beyond the initial post transplant period.
Leuk Res. 2018 Sep 05;73:67-75
Savoie ML, Bence-Bruckler I, Huebsch LB, Lalancette M, Hillis C, Walker I, Lipton JH, Forrest DL, Kim DDH
Haematologica. 2018 Aug 09;:
Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE
Blood Res. 2018 Jun;53(2):172-174
Kavanagh S, Bril V, Lipton JH
Ann Hematol. 2018 Jun 11;:
Khalil MMI, Messner HA, Lipton JH, Kim DD, Viswabandya A, Thyagu S, Deotare U, Michelis FV
Haematologica. 2018 May 17;:
Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ
Biol Blood Marrow Transplant. 2018 Apr 18;:
Coomes EA, Wolfe AJ, Michelis FV, Kim DD, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Deotare U
Bone Marrow Transplant. 2018 Mar;53(3):334-338
Uhm J, Shin E, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Kim DDH
Eur Respir J. 2018 Mar 15;:
Hirama T, Brode SK, Beswick J, Law AD, Lam W, Michelis FV, Thyagu S, Viswabandya A, Lipton JH, Messner HA, Kim DDH, Marras TK



Professor of Medicine, University of Toronto